GlassScriptPhysician profile
Christopher T Ogden
NPI 1659061141
$1,864.45
in general payments reported to CMS, 2019-2025
22 companies · $657 in 2025
The $657 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $321 · 2024: $886 · 2025: $657.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,864.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,864.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $373.73 | 2023-2025 | Evenity, Prolia, Otezla |
| Pfizer INC. | $238.68 | 2023-2025 | |
| Lilly USA, LLC | $185.81 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Astrazeneca Pharmaceuticals LP | $152.55 | 2023-2025 | Airsupra, Farxiga |
| Novo Nordisk INC | $143.07 | 2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $84.91 | 2024-2025 | Trelegy Ellipta, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $78.62 | 2024-2025 | Xifaxan, Trulance |
| Exact Sciences Corporation | $70.85 | 2024-2025 | Cologuard Collection Kit |
| Abbvie INC. | $69.07 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $66.98 | 2023 | Verquvo |
| Astellas Pharma US INC | $46.11 | 2024 | Veozah |
| Kiniksa Pharmaceuticals, LTD. | $44.13 | 2023 | Arcalyst |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.05 | 2023-2025 | Jardiance, Ofev |
| Edwards Lifesciences Corporation | $40.52 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Viatris Specialty LLC | $38.67 | 2025 | Yupelri |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $37.95 | 2024 | |
| Mylan Specialty L.P. | $34.37 | 2024 | Yupelri |
| Vertex Pharmaceuticals Incorporated | $31.63 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $31.33 | 2024 | |
| Janssen Pharmaceuticals, INC | $20.92 | 2023 | Xarelto |
| Philips North America LLC | $18.18 | 2024 | (Ak6) Vest Therapy |
| Idorsia Pharmaceuticals US INC | $15.32 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Ogden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.